Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
NCT07745361
This study is recruiting at 5 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
This Phase 2, open-label, multicenter study is conducted in patients with castration-resistant prostate cancer. Patients in this study receive MRT-2359, an investigational oral medicine, in combination with apalutamide, an oral medicine used to treat prostate cancer. The main purpose of the study is to assess whether this treatment combination can lower prostate-specific antigen (PSA) The study will also evaluate the safety and tolerability of the treatment combination and assess additional measures of anti-tumor activity.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Castration-Resistant Prostate Cancer (CRPC)
- Castration-Resistant Prostate Cancer
- Prostate Cancer
- Prostate Cancer (Adenocarcinoma)
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- Monte Rosa Therapeutics, Inc
- Last updated on ClinicalTrials.gov
- October 8, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- START Los Angeles · Los Angeles, CA
Nebraska · 1
- XCancer Omaha · Omaha, NE
New Jersey · 1
- START New Jersey · East Brunswick, NJ
Utah · 1
- START Mountain Region · West Valley City, UT
Washington · 1
- University of Washington Medical Center · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.